CR20120177A - Nuevos compuestos de espiropiperidina y el uso farmacéutico del mismo para el tratamiento de diabetes - Google Patents

Nuevos compuestos de espiropiperidina y el uso farmacéutico del mismo para el tratamiento de diabetes

Info

Publication number
CR20120177A
CR20120177A CR20120177A CR20120177A CR20120177A CR 20120177 A CR20120177 A CR 20120177A CR 20120177 A CR20120177 A CR 20120177A CR 20120177 A CR20120177 A CR 20120177A CR 20120177 A CR20120177 A CR 20120177A
Authority
CR
Costa Rica
Prior art keywords
diabetes
spiropiperidine
treatment
same
new compounds
Prior art date
Application number
CR20120177A
Other languages
English (en)
Inventor
Chafiq Hamdouchi
Jayana Pankaj Lineswala
Pranab Maiti
Original Assignee
Lilly Co Eli
Memory Pharm Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=43719548&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CR20120177(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Lilly Co Eli, Memory Pharm Corp filed Critical Lilly Co Eli
Publication of CR20120177A publication Critical patent/CR20120177A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/10—Spiro-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/438—The ring being spiro-condensed with carbocyclic or heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D221/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00
    • C07D221/02—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00 condensed with carbocyclic rings or ring systems
    • C07D221/20—Spiro-condensed ring systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Diabetes (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Emergency Medicine (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Un compuesto de la fórmula:o una sal del mismo farmacéuticamente aceptable así como también una composición farmacéutica, y un método para tratar diabetes.
CR20120177A 2009-10-15 2012-04-12 Nuevos compuestos de espiropiperidina y el uso farmacéutico del mismo para el tratamiento de diabetes CR20120177A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US25183909P 2009-10-15 2009-10-15
US30333410P 2010-02-11 2010-02-11

Publications (1)

Publication Number Publication Date
CR20120177A true CR20120177A (es) 2012-06-06

Family

ID=43719548

Family Applications (1)

Application Number Title Priority Date Filing Date
CR20120177A CR20120177A (es) 2009-10-15 2012-04-12 Nuevos compuestos de espiropiperidina y el uso farmacéutico del mismo para el tratamiento de diabetes

Country Status (25)

Country Link
US (1) US8383642B2 (es)
EP (1) EP2488500A1 (es)
JP (1) JP2013508279A (es)
KR (1) KR20120051777A (es)
CN (1) CN102574807A (es)
AR (1) AR078522A1 (es)
AU (1) AU2010307094A1 (es)
BR (1) BR112012008889A2 (es)
CA (1) CA2777775A1 (es)
CL (1) CL2012000921A1 (es)
CO (1) CO6531458A2 (es)
CR (1) CR20120177A (es)
DO (1) DOP2012000105A (es)
EA (1) EA201270560A1 (es)
EC (1) ECSP12011799A (es)
IL (1) IL218344A0 (es)
MA (1) MA33662B1 (es)
MX (1) MX2012004420A (es)
NZ (1) NZ598972A (es)
PE (1) PE20121437A1 (es)
PH (1) PH12012500705A1 (es)
TN (1) TN2012000152A1 (es)
TW (1) TW201124415A (es)
WO (1) WO2011046851A1 (es)
ZA (1) ZA201202560B (es)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PE20120834A1 (es) 2009-03-23 2012-07-25 Glenmark Pharmaceuticals Sa Derivados de furopirimidindiona como moduladores de trpa1
ES2456515T3 (es) 2009-03-23 2014-04-22 Glenmark Pharmaceuticals S.A. Derivados de pirimidindiona fusionados como moduladores de TRPA1
AR078948A1 (es) 2009-11-30 2011-12-14 Lilly Co Eli Compuestos de espiropiperidina, composicion farmaceutica que lo comprenden y su uso para preparar un medicamento util para tratar la diabetes
PH12012501456A1 (en) 2009-12-25 2012-10-29 Mochida Pharm Co Ltd Novel 3-hydroxy -5- arylisothiazole derivative
AU2011313191A1 (en) 2010-10-08 2013-05-02 Mochida Pharmaceutical Co., Ltd. Cyclic amide derivative
EP2683251B1 (en) 2011-03-11 2021-08-25 Intercontinental Great Brands LLC Method of forming multilayer confectionery
AR085990A1 (es) 2011-04-27 2013-11-13 Mochida Pharm Co Ltd Derivados de 1-oxido de 3-hidroxiisotiazol utiles en el tratamiento de la diabetes y composiciones farmaceuticas que los contienen
JPWO2012147516A1 (ja) 2011-04-28 2014-07-28 持田製薬株式会社 環状アミド誘導体
AR087451A1 (es) 2011-08-17 2014-03-26 Lilly Co Eli Derivado de 1,2,3,4-tetrahidroquinolina util para tratamiento de diabetes
WO2013139341A1 (en) * 2012-03-20 2013-09-26 Syddansk Universitet Gpr120 receptor modulators
WO2013185766A1 (en) * 2012-06-15 2013-12-19 Syddansk Universitet Gpr120 receptor modulators
UY35143A (es) 2012-11-16 2014-05-30 Bristol Myers Squibb Co Derivados de dihidropirazol como moduladores del receptor acoplado a la proteína gpr40 g
KR101569522B1 (ko) * 2013-04-18 2015-11-17 현대약품 주식회사 신규한 3-(4-(벤질옥시)페닐)헥스-4-이노익 산 유도체, 이의 제조방법 및 이를 유효성분으로 함유하는 대사성 질환의 예방 또는 치료용 약학적 조성물
CN105722841A (zh) * 2013-11-14 2016-06-29 卡迪拉保健有限公司 新型杂环化合物
US20150351889A1 (en) 2014-06-05 2015-12-10 Vivex Biomedical Inc. Dynamic Biometric Mesh
EP3207928B1 (en) * 2014-10-17 2021-03-10 Hyundai Pharm Co., Ltd. Composite preparation, containing novel 3-(4-(benzyloxy)phenyl)hex-4-inoic acid derivative and another active ingredient, for preventing or treating metabolic diseases
BR102018007822A2 (pt) 2017-04-20 2018-11-06 Gilead Sciences, Inc. composto, métodos para inibir pd-1, pd-l1 e/ou interação de pd-1/pd-l1 e para tratamento de câncer, composição farmacêutica, e, kit para tratamento de ou prevenção de câncer ou uma doença ou condição
CN109666027A (zh) * 2017-10-17 2019-04-23 中国科学院上海药物研究所 一类酰胺结构的gpr40激动剂化合物及其用途
DK3737470T5 (da) 2018-01-08 2024-05-27 Celon Pharma Sa 3-phenyl-4-hexynsyrederivater som gpr40-agonister
WO2019160882A1 (en) 2018-02-13 2019-08-22 Gilead Sciences, Inc. Pd-1/pd-l1 inhibitors
KR102591947B1 (ko) 2018-04-19 2023-10-25 길리애드 사이언시즈, 인코포레이티드 Pd-1/pd-l1 억제제
PE20210642A1 (es) 2018-07-13 2021-03-23 Gilead Sciences Inc Inhibidores de pd-1/pd-l1
US11236085B2 (en) 2018-10-24 2022-02-01 Gilead Sciences, Inc. PD-1/PD-L1 inhibitors
JP2022552655A (ja) 2019-10-07 2022-12-19 キャリーオペ，インク． Ｇｐｒ１１９アゴニスト
MX2022010548A (es) 2020-02-28 2022-09-23 Kallyope Inc Agonistas de gpr40.
MX2022014505A (es) 2020-05-19 2022-12-13 Kallyope Inc Activadores de la ampk.
CA3183575A1 (en) 2020-06-26 2021-12-30 Iyassu Sebhat Ampk activators

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2033644A1 (en) 2001-04-18 2009-03-11 Euro-Celtique S.A. Spiroindene and spiroindane compounds
CA2520114A1 (en) * 2003-04-04 2004-10-21 Merck & Co., Inc. Acylated spiropiperidine derivatives as melanocortin-4 receptor agonists
US7504506B2 (en) 2003-11-04 2009-03-17 Elixir Pharmaceuticals, Inc. Therapeutic compounds and uses thereof
WO2005051890A1 (en) 2003-11-19 2005-06-09 Smithkline Beecham Corporation Aminophenylcyclopropyl carboxylic acids and derivatives as agonists to gpr40
EP1737809B1 (en) 2004-02-27 2013-09-18 Amgen, Inc Compounds, pharmaceutical compositions and methods for use in treating metabolic disorders
JP4859665B2 (ja) 2004-03-30 2012-01-25 武田薬品工業株式会社 アルコキシフェニルプロパン酸誘導体
US7582803B2 (en) 2005-09-14 2009-09-01 Amgen Inc. Conformationally constrained 3-(4-hydroxy-phenyl)-substituted-propanoic acids useful for treating metabolic disorders
EP2061760A1 (en) 2006-09-07 2009-05-27 Amgen, Inc Benzo-fused compounds for use in treating metabolic disorders
TWI421070B (zh) 2007-10-26 2014-01-01 Japan Tobacco Inc 螺化合物及其醫藥用途
EP2224803B1 (en) 2007-11-21 2014-04-02 Janssen Pharmaceutica N.V. Spiropiperidines for use as tryptase inhibitors
AR078948A1 (es) 2009-11-30 2011-12-14 Lilly Co Eli Compuestos de espiropiperidina, composicion farmaceutica que lo comprenden y su uso para preparar un medicamento util para tratar la diabetes

Also Published As

Publication number Publication date
AR078522A1 (es) 2011-11-16
ECSP12011799A (es) 2012-07-31
PE20121437A1 (es) 2012-10-26
CL2012000921A1 (es) 2012-09-14
CA2777775A1 (en) 2011-04-21
NZ598972A (en) 2013-06-28
EA201270560A1 (ru) 2012-09-28
DOP2012000105A (es) 2013-01-31
JP2013508279A (ja) 2013-03-07
EP2488500A1 (en) 2012-08-22
CO6531458A2 (es) 2012-09-28
PH12012500705A1 (en) 2012-10-29
MX2012004420A (es) 2012-05-08
MA33662B1 (fr) 2012-10-01
US20110092531A1 (en) 2011-04-21
WO2011046851A1 (en) 2011-04-21
TW201124415A (en) 2011-07-16
AU2010307094A1 (en) 2012-04-19
KR20120051777A (ko) 2012-05-22
IL218344A0 (en) 2012-04-30
CN102574807A (zh) 2012-07-11
BR112012008889A2 (pt) 2019-09-24
US8383642B2 (en) 2013-02-26
TN2012000152A1 (en) 2013-12-12
ZA201202560B (en) 2013-09-25

Similar Documents

Publication Publication Date Title
ECSP12011799A (es) Compuestos de espiropiperidina y uso farmacéutico de los mismos
ECSP12011930A (es) Nuevos compuestos de espiropiperidina
BR112012026767A2 (pt) composto, sal farmaceuticamente aceitável de um composto, composição farmacêutica, método para tratar ou previnir distúrbios, e, uso de um composto ou sal
ECSP099436A (es) Acilaminopirazoles como inhibidores de fgfr
UY32153A (es) Inhibidores de piridomidinona de pi13ka(alfa) y mtor
CO6620055A2 (es) Ciertas amino-pirimidinas, composiciones de las mismas y métodos para el uso de los mismos
UY32062A (es) Inhibidores de beta-secretasa
DOP2011000260A (es) Pirimidinas fusionadas
UY31215A1 (es) Compuestos de morfolino pirimidina, procesos para su preparacion, composiciones farmacéuticas conteniéndolos y su uso en terapia.
NI200900184A (es) Uso de compuestos inhibidores de quinaxolina de pi3k-alfa para el tratamiento del cáncer.
CR20140052A (es) Un derivado novedoso de 1,2,3,4-tetrahidroquinolina útil para el tratamiento de diabetes
BRPI1015983A2 (pt) composto, uso do composto, método para tratar um paciente, e, composição farmacêutica.
CL2013002417A1 (es) Compuestos derivados de fluoropiridinona; composición farmacéutica que los comprende; y su uso en el tratamiento de infecciones bacterianas.
CL2014001154A1 (es) Compuestos derivados antibioticos de 2-oxo-oxazolidin-3,5-diilo de formula i; composicion farmaceutica; uso para la prevencion o tratamiento de una infeccion bacteriana.
CR11684A (es) Dihidropirazolonas sustituidas de hif-propil-4- como inhibidores hidroxilasa
SG194463A1 (en) Glycoside derivatives and their uses for the treatment of diabetes
AR085616A1 (es) Composicion farmaceutica inhalable que comprende glicopirrolato, uso
ECSP10010168A (es) Benzotiazolas como moduladores del receptor de ghrelina
CL2014002845A1 (es) Compuestos derivados de pirazol inhibidores de sglt1; metodo para tratar la diabetes; composicion farmaceutica; uso del compuesto para el tratamiento de la diabetes tipo 1 y tipo 2.
CO6460763A2 (es) Métodos y formulaciones ectoparasiticidas
AR080025A1 (es) Derivados de 8-aza-biciclo[3,2,1] oct-3-iloxi)-cromen-2-ona, utiles como inhibidores de la recaptacion del neurotransmisor monoamina
CO6382120A2 (es) Compuestos ciclopropilo
ECSP13012653A (es) COMPUESTOS DE OXAZOL[5,4-b]PIRIDIN-5-ILO Y SU USO PARA EL TRATAMIENTO DE CÁNCER
UY33806A (es) ?compuestos novedosos de imidazoquinolina, composiciones que los contienen y su uso en el tratamiento de enfermedades mediadas por tlr7?
WO2014147578A3 (en) Antibacterial compounds against drug resistant bacteria

Legal Events

Date Code Title Description
FA Abandonment or withdrawal (granting procedure)